Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Current Deferred Revenue (2016 - 2025)

OptimizeRx (OPRX) has disclosed Current Deferred Revenue for 16 consecutive years, with $503000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 6.34% to $503000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $503000.0 through Dec 2025, up 6.34% year-over-year, with the annual reading at $503000.0 for FY2025, 6.34% up from the prior year.
  • Current Deferred Revenue hit $503000.0 in Q4 2025 for OptimizeRx, up from $395000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.4 million in Q4 2021 to a low of $164000.0 in Q4 2022.
  • Historically, Current Deferred Revenue has averaged $616661.9 across 5 years, with a median of $493500.0 in 2025.
  • Biggest five-year swings in Current Deferred Revenue: soared 386.33% in 2021 and later tumbled 88.2% in 2022.
  • Year by year, Current Deferred Revenue stood at $1.4 million in 2021, then crashed by 88.2% to $164000.0 in 2022, then increased by 4.88% to $172000.0 in 2023, then soared by 175.0% to $473000.0 in 2024, then rose by 6.34% to $503000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for OPRX at $503000.0 in Q4 2025, $395000.0 in Q3 2025, and $484000.0 in Q2 2025.